What the research shows
What the studies say — and what we see.
The procedure we’ve done the most, and the one with the most research behind
it, is genicular artery embolization for knee
arthritis. The knee has been studied the longest and most widely, and the finding is
consistent: block the abnormal blood vessels feeding an inflamed joint, and the pain settles.
Doctors then asked whether the same approach would help other joints — and the results
in shoulders, hips, and even the plantar fascia in the foot follow the same pattern as the
knee.
That matches what we see in our own practice. We’ve performed more than
700 knee embolizations, along with shoulders, hips, and feet, and in our experience all of
them are highly effective — most of the patients we treat get real, meaningful
relief. The hip research is newer and smaller than the knee’s, and we’ll
always tell you that. Here’s what it shows.
The hip studies tell a consistent story. In the largest — 49
patients with hip arthritis or bursitis, followed for a year — average pain
fell from 7.8 to 4.0 out of 10, and about 3 in 4 of those followed the full year had at
least a 50% improvement in pain or function.¹ The bursitis finding matters to us, because
we see a lot of it: in that study, patients whose problem was purely trochanteric bursitis
did just as well as the arthritis patients.¹ In an earlier six-month series — 13
patients, 10 of them with bursitis — the standard hip pain-and-function score fell from
77 to 27.³ And in a 31-patient bursitis series, 21 of 38 hips reached mild pain
(0–3 out of 10) at last follow-up, 7 more improved to moderate, and 9 didn’t
improve — worth knowing going in.² That’s why we offer embolization for
severe, recurring bursitis rather than sending you back for a fourth cortisone shot.
One study looked only at people who couldn’t have a hip
replacement — 18 patients over 60, each with a medical reason surgery wasn’t safe
— and saw pain fall from 7.8 to 4.3 out of 10 at 12 weeks, with no complications. Its
authors called embolization a bridge between conservative care and surgery. That’s how
we think of it too.⁴
And the newest series — 41 patients in Berlin, every one with confirmed
hip arthritis, most of it moderate to severe on X-ray — shows the same shape: pain
7 to 4 out of 10 at six months, holding at twelve; about 2 in 3 with a
meaningful pain improvement and roughly 9 in 10 with a meaningful gain in daily function; no
serious complications and no damage to the ball of the hip joint. The two patients who
didn’t respond went on to hip replacement afterward — embolization didn’t
close that door.⁵
Across every published series, the procedure has been safe and well
tolerated — no serious complications; the side effects were groin bruises, a
temporary patch of thigh numbness and a brief patch of skin discoloration, all cleared on
their own¹ ² ³ ⁴ ⁵ — and it leaves nothing
permanent behind. For a hip that’s “not bad enough” to replace and too bad
to live with, that’s what makes it worth a conversation: a safe, reliable, effective
treatment that doesn’t involve an incision or an implant.
We do a complimentary benefits check before any procedure. No
surprises.
Sources: 1. Cavalheiro et al., HipE Study,
Cardiovasc Intervent Radiol 2026;49(7):1295–1305 — prospective single-arm, single-center;
49 treated, 37 completed 12 months (31 hip OA, 6 pure trochanteric pain syndrome);
imipenem/cilastatin; VAS 7.84→3.97, WOMAC 54→24; clinical success (≥50%
reduction in WOMAC or VAS) 73% of completers; two grade 1a groin hematomas; no
significant difference between the OA and pure-GTPS subgroups. 2. Giordani et al., Latino-Hip
cohort, Cardiovasc Intervent Radiol 2025;48(4):538–542 — single-center registry
(retrospective analysis of a prospective cohort), 31 patients / 38 joints with
trochanteric pain syndrome refractory to conservative care; at last follow-up 21 joints VAS
0–3, 7 joints VAS 4–6, 9 joints unimproved (VAS 7–10); one lost to
follow-up; two minor complications (posterior thigh numbness, resolved within 30 days).
3. Correa et al., Cardiovasc Intervent Radiol 2022;45:1710–1715 — 13 patients (10 GTPS,
3 hip OA), 6 months: WOMAC 77→27, VAS 10→2; two transient numbness. 4. Feier et al.,
Cureus 2025;17(11):e96060 — 18 patients ≥60 with a contraindication to hip replacement,
Tönnis grade I–II: VAS 7.8→4.3 and Harris Hip Score 45.5→62.1 at 12
weeks; no adverse events. 5. Fleckenstein et al., Cardiovasc Intervent Radiol 2026;49:1352–1361
— retrospective single-center, 41 patients with radiographic hip OA (KL III 68%, KL IV 27%),
≥3 months failed conservative care; technical success 40/41; median NRS pain 7→4 at 6 and 12
months; MCID reached by 64% (pain) and 85–92% (HOOS domains) at 12 months; 12-month follow-up in
28/41; no major or moderate adverse events, 3 transient skin discolorations; two KL IV non-responders
proceeded to hip replacement at 7 and 9 months. Sources 1–2 abstract-verified, 3–5 full
text — full texts before any print or ad use.